(+)-schisandrin B multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of GLS2 mRNA] CTD PMID:31150632 1,2-dimethylhydrazine increases expression ISO RGD:735898 6480464 1, 2-Dimethylhydrazine results in increased expression of GLS2 mRNA CTD PMID:22206623 1-naphthyl isothiocyanate decreases expression EXP 6480464 1-Naphthylisothiocyanate results in decreased expression of GLS2 mRNA CTD PMID:25380136 17beta-estradiol decreases expression ISO RGD:1604019 6480464 Estradiol results in decreased expression of GLS2 mRNA CTD PMID:20106945 17beta-estradiol multiple interactions ISO RGD:1604019 6480464 [Estradiol co-treated with TGFB1 protein] results in decreased expression of GLS2 mRNA CTD PMID:30165855 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions EXP 6480464 [3 more ... CTD PMID:16984957 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1604019 6480464 Tetrachlorodibenzodioxin results in decreased expression of GLS2 mRNA CTD PMID:20106945 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:735898 6480464 Tetrachlorodibenzodioxin results in decreased expression of GLS2 mRNA CTD PMID:26290441 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of GLS2 mRNA CTD PMID:16054898 more ... 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:735898 6480464 Tetrachlorodibenzodioxin affects the expression of GLS2 mRNA CTD PMID:21570461 2,4-dinitrotoluene affects expression EXP 6480464 2, 4-dinitrotoluene affects the expression of GLS2 mRNA CTD PMID:21346803 2,6-dinitrotoluene affects expression EXP 6480464 2, 6-dinitrotoluene affects the expression of GLS2 mRNA CTD PMID:21346803 2-nitrofluorene decreases expression EXP 6480464 2-nitrofluorene results in decreased expression of GLS2 mRNA CTD PMID:14600272 3,3',4,4',5-pentachlorobiphenyl multiple interactions EXP 6480464 [3 more ... CTD PMID:16984957 3,3',4,4',5-pentachlorobiphenyl decreases expression EXP 6480464 3 more ... CTD PMID:16984957 , PMID:20959002 3,3',5,5'-tetrabromobisphenol A decreases expression EXP 6480464 tetrabromobisphenol A results in decreased expression of GLS2 mRNA CTD PMID:27914987 4,4'-diaminodiphenylmethane decreases expression EXP 6480464 4, 4'-diaminodiphenylmethane results in decreased expression of GLS2 mRNA CTD PMID:25380136 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one decreases expression EXP 6480464 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in decreased expression of GLS2 mRNA CTD PMID:14600272 6-propyl-2-thiouracil decreases expression EXP 6480464 Propylthiouracil results in decreased expression of GLS2 mRNA CTD PMID:24780913 acetamide decreases expression EXP 6480464 acetamide results in decreased expression of GLS2 mRNA CTD PMID:31881176 acrylamide affects expression EXP 6480464 Acrylamide affects the expression of GLS2 mRNA CTD PMID:28959563 aflatoxin B1 affects expression ISO RGD:1604019 6480464 Aflatoxin B1 affects the expression of GLS2 protein CTD PMID:20106945 aflatoxin B1 decreases methylation ISO RGD:1604019 6480464 Aflatoxin B1 results in decreased methylation of GLS2 gene CTD PMID:27153756 aflatoxin B1 increases expression ISO RGD:1604019 6480464 Aflatoxin B1 results in increased expression of GLS2 mRNA CTD PMID:21632981 more ... aflatoxin B1 decreases expression EXP 6480464 Aflatoxin B1 results in decreased expression of GLS2 mRNA CTD PMID:22484513 aflatoxin B1 decreases expression ISO RGD:735898 6480464 Aflatoxin B1 results in decreased expression of GLS2 mRNA CTD PMID:19770486 amiodarone affects expression EXP 6480464 Amiodarone affects the expression of GLS2 mRNA CTD PMID:18355885 amitriptyline affects expression EXP 6480464 Amitriptyline affects the expression of GLS2 mRNA CTD PMID:18355885 arsenous acid affects response to substance ISO RGD:1604019 6480464 GLS2 protein affects the susceptibility to Arsenic Trioxide CTD PMID:24276018 benzo[a]pyrene increases expression ISO RGD:1604019 6480464 Benzo(a)pyrene results in increased expression of GLS2 mRNA CTD PMID:20106945 more ... benzo[a]pyrene decreases expression ISO RGD:1604019 6480464 Benzo(a)pyrene results in decreased expression of GLS2 mRNA CTD PMID:32234424 benzo[a]pyrene decreases methylation ISO RGD:1604019 6480464 Benzo(a)pyrene results in decreased methylation of GLS2 exon CTD PMID:27901495 benzo[a]pyrene increases methylation ISO RGD:1604019 6480464 Benzo(a)pyrene results in increased methylation of GLS2 promoter CTD PMID:27901495 beta-naphthoflavone multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of GLS2 mRNA CTD PMID:18164116 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of GLS2 mRNA CTD PMID:25181051 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of GLS2 mRNA CTD PMID:30816183 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of GLS2 mRNA CTD PMID:30903817 cadmium dichloride increases methylation EXP 6480464 Cadmium Chloride results in increased methylation of GLS2 promoter CTD PMID:22457795 cadmium dichloride decreases expression EXP 6480464 Cadmium Chloride results in decreased expression of GLS2 mRNA CTD PMID:25993096 carbamazepine affects expression ISO RGD:1604019 6480464 Carbamazepine affects the expression of GLS2 mRNA CTD PMID:25979313 carbon nanotube decreases expression ISO RGD:735898 6480464 Nanotubes, Carbon analog results in decreased expression of GLS2 mRNA, Nanotubes, Carbon results in decreased expression of GLS2 mRNA CTD PMID:25620056 cisplatin increases expression ISO RGD:1604019 6480464 Cisplatin results in increased expression of GLS2 mRNA CTD PMID:27392435 cisplatin multiple interactions ISO RGD:1604019 6480464 [Cisplatin results in decreased susceptibility to Cisplatin] which results in increased expression of GLS2 mRNA CTD PMID:30871063 clofibric acid affects expression EXP 6480464 Clofibric Acid affects the expression of GLS2 mRNA CTD PMID:17602206 clomipramine affects expression EXP 6480464 Clomipramine affects the expression of GLS2 mRNA CTD PMID:18355885 copper(II) sulfate decreases expression ISO RGD:1604019 6480464 Copper Sulfate results in decreased expression of GLS2 mRNA CTD PMID:19549813 cyclosporin A decreases expression ISO RGD:1604019 6480464 Cyclosporine results in decreased expression of GLS2 mRNA CTD PMID:20106945 , PMID:25562108 cyproconazole decreases expression ISO RGD:735898 6480464 cyproconazole results in decreased expression of GLS2 mRNA CTD PMID:22334560 diarsenic trioxide affects response to substance ISO RGD:1604019 6480464 GLS2 protein affects the susceptibility to Arsenic Trioxide CTD PMID:24276018 dimethylarsinic acid increases expression ISO RGD:1604019 6480464 Cacodylic Acid results in increased expression of GLS2 mRNA CTD PMID:17720352 dorsomorphin multiple interactions ISO RGD:1604019 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS2 mRNA CTD PMID:27188386 doxorubicin increases expression ISO RGD:1604019 6480464 Doxorubicin results in increased expression of GLS2 mRNA CTD PMID:28940058 , PMID:30031762 endosulfan decreases expression EXP 6480464 Endosulfan results in decreased expression of GLS2 mRNA CTD PMID:29391264 entinostat increases expression ISO RGD:1604019 6480464 entinostat results in increased expression of GLS2 mRNA CTD PMID:26272509 entinostat multiple interactions ISO RGD:1604019 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS2 mRNA CTD PMID:27188386 epoxiconazole decreases expression ISO RGD:735898 6480464 epoxiconazole results in decreased expression of GLS2 mRNA CTD PMID:22334560 etoposide increases expression ISO RGD:1604019 6480464 Etoposide results in increased expression of GLS2 mRNA CTD PMID:21527772 , PMID:29397400 flavonoids decreases expression EXP 6480464 Flavonoids results in decreased expression of GLS2 mRNA CTD PMID:18035473 flutamide decreases expression EXP 6480464 Flutamide results in decreased expression of GLS2 mRNA CTD PMID:24136188 glafenine decreases expression EXP 6480464 Glafenine results in decreased expression of GLS2 mRNA CTD PMID:24136188 hydrogen peroxide affects response to substance ISO RGD:1604019 6480464 GLS2 protein affects the susceptibility to Hydrogen Peroxide CTD PMID:24276018 imipramine affects expression EXP 6480464 Imipramine affects the expression of GLS2 mRNA CTD PMID:18355885 ketoconazole affects expression EXP 6480464 Ketoconazole affects the expression of GLS2 mRNA CTD PMID:18355885 leflunomide decreases expression EXP 6480464 leflunomide results in decreased expression of GLS2 mRNA CTD PMID:24136188 lipopolysaccharide multiple interactions ISO RGD:1604019 6480464 [Lipopolysaccharides co-treated with resveratrol] results in increased expression of GLS2 mRNA CTD PMID:26667767 methapyrilene decreases expression EXP 6480464 Methapyrilene results in decreased expression of GLS2 mRNA CTD PMID:30467583 N-nitrosodiethylamine multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of GLS2 mRNA, [Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of GLS2 mRNA CTD PMID:18164116 , PMID:28943392 N-nitrosodiethylamine multiple interactions ISO RGD:735898 6480464 [Diethylnitrosamine co-treated with Phenobarbital] results in decreased expression of GLS2 mRNA CTD PMID:24535843 N-nitrosodimethylamine decreases expression EXP 6480464 Dimethylnitrosamine results in decreased expression of GLS2 mRNA CTD PMID:14600272 , PMID:25380136 nefazodone decreases expression EXP 6480464 nefazodone results in decreased expression of GLS2 mRNA CTD PMID:24136188 nickel atom decreases expression ISO RGD:1604019 6480464 Nickel results in decreased expression of GLS2 mRNA CTD PMID:24768652 nimesulide decreases expression EXP 6480464 nimesulide results in decreased expression of GLS2 mRNA CTD PMID:24136188 O-methyleugenol decreases expression ISO RGD:1604019 6480464 methyleugenol results in decreased expression of GLS2 mRNA CTD PMID:32234424 paracetamol affects expression ISO RGD:735898 6480464 Acetaminophen affects the expression of GLS2 mRNA CTD PMID:17562736 paracetamol decreases expression ISO RGD:1604019 6480464 Acetaminophen results in decreased expression of GLS2 mRNA CTD PMID:29067470 paracetamol increases expression ISO RGD:1604019 6480464 Acetaminophen results in increased expression of GLS2 mRNA CTD PMID:22230336 , PMID:25704631 perfluorononanoic acid decreases expression ISO RGD:1604019 6480464 perfluorononanoic acid results in decreased expression of GLS2 mRNA CTD PMID:32588087 perfluorooctanoic acid affects expression ISO RGD:735898 6480464 perfluorooctanoic acid affects the expression of GLS2 mRNA CTD PMID:18281256 perfluorooctanoic acid decreases expression EXP 6480464 perfluorooctanoic acid results in decreased expression of GLS2 mRNA CTD PMID:20452409 phenobarbital decreases expression EXP 6480464 Phenobarbital results in decreased expression of GLS2 mRNA CTD PMID:19162173 phenobarbital multiple interactions ISO RGD:735898 6480464 [Diethylnitrosamine co-treated with Phenobarbital] results in decreased expression of GLS2 mRNA CTD PMID:24535843 piperonyl butoxide decreases expression EXP 6480464 Piperonyl Butoxide results in decreased expression of GLS2 mRNA CTD PMID:22484513 pirinixic acid multiple interactions ISO RGD:1604019 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of GLS2 mRNA CTD PMID:19710929 pirinixic acid decreases expression ISO RGD:735898 6480464 pirinixic acid results in decreased expression of GLS2 mRNA CTD PMID:23811191 pirinixic acid decreases expression EXP 6480464 pirinixic acid results in decreased expression of GLS2 mRNA CTD PMID:17164430 , PMID:19162173 potassium dichromate decreases expression ISO RGD:735898 6480464 Potassium Dichromate results in decreased expression of GLS2 mRNA CTD PMID:23608068 pravastatin decreases expression ISO RGD:735898 6480464 Pravastatin results in decreased expression of GLS2 mRNA CTD PMID:27225895 pravastatin decreases expression EXP 6480464 Pravastatin results in decreased expression of GLS2 mRNA CTD PMID:27225895 pregnenolone 16alpha-carbonitrile decreases expression EXP 6480464 Pregnenolone Carbonitrile results in decreased expression of GLS2 mRNA CTD PMID:19162173 propiconazole decreases expression ISO RGD:735898 6480464 propiconazole results in decreased expression of GLS2 mRNA CTD PMID:22334560 quercetin increases expression ISO RGD:1604019 6480464 Quercetin results in increased expression of GLS2 mRNA CTD PMID:21632981 resveratrol multiple interactions ISO RGD:1604019 6480464 [Lipopolysaccharides co-treated with resveratrol] results in increased expression of GLS2 mRNA CTD PMID:26667767 SB 431542 multiple interactions ISO RGD:1604019 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS2 mRNA CTD PMID:27188386 silicon dioxide decreases expression ISO RGD:1604019 6480464 Silicon Dioxide analog results in decreased expression of GLS2 mRNA CTD PMID:25895662 sodium arsenite decreases expression ISO RGD:1604019 6480464 sodium arsenite results in decreased expression of GLS2 mRNA CTD PMID:29301061 sodium dichromate decreases expression EXP 6480464 sodium bichromate results in decreased expression of GLS2 mRNA CTD PMID:25993096 Soman increases expression EXP 6480464 Soman results in increased expression of GLS2 mRNA CTD PMID:19281266 sunitinib increases expression ISO RGD:1604019 6480464 Sunitinib results in increased expression of GLS2 mRNA CTD PMID:31533062 tetrachloromethane decreases expression ISO RGD:735898 6480464 Carbon Tetrachloride results in decreased expression of GLS2 mRNA CTD PMID:27339419 , PMID:31919559 tetrachloromethane multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of GLS2 mRNA] CTD PMID:31150632 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of GLS2 mRNA CTD PMID:31150632 thioacetamide decreases expression EXP 6480464 Thioacetamide results in decreased expression of GLS2 mRNA CTD PMID:23411599 thioacetamide multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of GLS2 mRNA CTD PMID:28943392 urethane decreases expression ISO RGD:1604019 6480464 Urethane results in decreased expression of GLS2 mRNA CTD PMID:28818685 valdecoxib decreases expression EXP 6480464 valdecoxib results in decreased expression of GLS2 mRNA CTD PMID:24136188 valproic acid affects expression ISO RGD:1604019 6480464 Valproic Acid affects the expression of GLS2 mRNA CTD PMID:25979313 valproic acid decreases methylation ISO RGD:1604019 6480464 Valproic Acid results in decreased methylation of GLS2 gene CTD PMID:29154799 valproic acid increases expression ISO RGD:1604019 6480464 Valproic Acid results in increased expression of GLS2 mRNA CTD PMID:29154799 vinclozolin increases expression EXP 6480464 vinclozolin results in increased expression of GLS2 mRNA CTD PMID:23869203 vinclozolin decreases expression EXP 6480464 vinclozolin results in decreased expression of GLS2 mRNA CTD PMID:23034163 
Gene-Chemical Interaction Annotations
